ArticleBiotechnology for biofuels and bioproducts2023
Systems metabolic engineering of Escherichia coli for hyper-production of 5‑aminolevulinic acid.
Article in Biotechnology for biofuels and bioproducts, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 52 citations in OpenAlex.
- Small Regulatory RNAs in Prokaryotes: Key Features, Identification, Environmental Roles, and Applications.Microorganisms · 2026Review
- Microbial production of xanthohumol driven by synthetic biology approaches.World journal of microbiology & biotechnology · 2026Review
- Recent advances in nonprotein amino acids: insights from function to biosynthesis.Journal of animal science and biotechnology · 2026Review
- Metabolic engineering ofApplied and environmental microbiology · 2026Article
- Systems metabolic engineering of dual pathways with stage-specific activation for high-level 5-aminolevulinic acid production inSynthetic and systems biotechnology · 2026Article
- Metabolic Engineering of the 5-Aminolevulinate Biosynthetic Pathway in E. coli Improves Efficiency of Hemoprotein-Based Biocatalysis.Angewandte Chemie (International ed. in English) · 2025Article
- Combined metabolic and enzymatic engineering forSynthetic and systems biotechnology · 2025Article
- Construction of a genome-engineered stable 5-aminolevulinic acid producingSynthetic and systems biotechnology · 2025Article
- Elucidating the Mechanism of Temporal Adaptation to Hydrogen Peroxide-Induced Oxidative Stress in Corynebacterium glutamicum.Microbial biotechnology · 2025Article
- Manipulating Intracellular Oxidative Conditions to Enhance Porphyrin Production inBioengineering (Basel, Switzerland) · 2025Article
- Review
- On the Possibility of Using 5-Aminolevulinic Acid in the Light-Induced Destruction of Microorganisms.International journal of molecular sciences · 2024Review
- Correction: Systems metabolic engineering of Escherichia coli for hyper-production of 5-aminolevulinic acid.Biotechnology for biofuels and bioproducts · 2023Article
- Diverse mechanisms of bioproduction heterogeneity in fermentation and their control strategies.Journal of industrial microbiology & biotechnology · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
background5-Aminolevulinic acid (5-ALA) is a promising biostimulant, feed nutrient, and photodynamic drug with wide applications in modern agriculture and therapy. Although microbial production of 5-ALA has been improved realized by using metabolic engineering strategies during the past few years, there is still a gap between the present production level and the requirement of industrialization.
resultsIn this study, pathway, protein, and cellular engineering strategies were systematically employed to construct an industrially competitive 5-ALA producing Escherichia coli. Pathways involved in precursor supply and product degradation were regulated by gene overexpression and synthetic sRNA-based repression to channel metabolic flux to 5-ALA biosynthesis. 5-ALA synthase was rationally engineered to release the inhibition of heme and improve the catalytic activity. 5-ALA transport and antioxidant defense systems were targeted to enhance cellular tolerance to intra- and extra-cellular 5-ALA. The final engineered strain produced 30.7 g/L of 5-ALA in bioreactors with a productivity of 1.02 g/L/h and a yield of 0.532 mol/mol glucose, represent a new record of 5-ALA bioproduction.
conclusionsAn industrially competitive 5-ALA producing E. coli strain was constructed with the metabolic engineering strategies at multiple layers (protein, pathway, and cellular engineering), and the strategies here can be useful for developing industrial-strength strains for biomanufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.